| ||||||||||||||
|
|
|||||||||||||

Department of Anaesthesiology, *Queen Mary Hospital; and
The University of Hong Kong, Queen Mary Hospital, Pokfulam Road, Hong Kong
Address correspondence and reprint requests to Dr. Michael G. Irwin, Department of Anaesthesiology, University of Hong Kong, Room 424, K Block, Queen Mary Hospital, Pokfulam Road, Hong Kong. Address e-mail to mgirwin{at}hkucc.hku.hk.
Propofol is frequently used for sedation, induction, and maintenance of anesthesia. It is, however, associated with pain on injection. Propofol-Lipuro® has an oil phase that allows a larger proportion of propofol to be dissolved in it and, thereby, apparently reduces pain. However, studies investigating this have had methodological limitations. We devised a randomized, double-blind, crossover study comparing pain on injection between two preparations of propofol, Diprivan® and Propofol-Lipuro®, in subanesthetic doses. Sixty healthy patients received the drugs in random order via the same injection site separated by 10 min and a 0.9% saline flush. Pain was assessed using a verbal rating score (VRS) during and at 1-min time points after injection. Differences in VRS between the two propofol preparations at different time points in each patient were analyzed. In patients who were given Diprivan® first followed by Propofol-Lipuro® (group D-P), pain was significantly reduced with Propofol-Lipuro® compared with Diprivan® during initial injection (median difference in VRS = 2 [interquartile range 02], P = 0.002) and at 1 min (3 [04], P < 0.001). In patients who were given Propofol-Lipuro® first followed by Diprivan® (group P-D), no significant differences in VRS were shown. Propofol-Lipuro® is associated with reduced injection pain compared with Diprivan® and also seems to attenuate subsequent injection pain of Diprivan® when administered first. The mechanism is unknown, but may be related to a reduction in the concentration of propofol in the aqueous phase.
|